Skip to main content

Table 1 Baseline characteristics of the patients and laboratory data at initiation of tolvaptan

From: Impact of continued administration of tolvaptan on cirrhotic patients with ascites

 

Total (n = 170)

Discontinued* (n = 90)

Continued** (n = 37)

p-value * vs. **

Age (years)

63 (21–90)

60 (21–85)

63 (22–90)

0.28

Sex (% of males)

95/170 (56%)

47/90 (52%)

23/37 (62%)

0.31

BW (kg)

61.9 (34.4–143.6)

61.6 (37.4–98.9)

62.9 (34.4–143.6)

0.48

BW after 1 week (kg)

60.9 (32.7–136.2)

61.5 (36.3–103.8)

61.0 (32.7–136.2)

0.75

BW reduction after 1 week (kg)

1.5 (−6.2–17.2)

1.1 (−6.2–7.5)

2.0 (−3.4–17.2)

0.03

Urine volume (mL)

1595 (120–6630)

1450 (120–6630)

1690 (195–4460)

0.77

Etiology of liver disease (%)

   

0.07

 HCV

48 (28%)

28 (31%)

6 (16%)

 

 HBV

12 (7%)

4 (4%)

4 (11%)

 

 ALD

48 (28%)

22 (24%)

15 (41%)

 

 NAFLD

19 (11%)

7 (8%)

5 (14%)

 

 PBC

17 (10%)

7 (8%)

4 (11%)

 

 Others

31 (18%)

24 (27%)

4 (11%)

 

Complication (%)

 Gastroesophageal varices

109/160 (68%)

62/82 (76%)

21/37 (57%)

0.04

 Hepatocellular carcinoma

54/170 (32%)

26/90 (29%)

13/37 (35%)

0.51

 Hepatic encephalopathy

46/170 (27%)

33/90 (37%)

8/37 (22%)

0.10

Diuretics

 Furosemide dose (mg/day)

20 (0–160)

20 (0–120)

20 (0–80)

0.48

 Spironolactone dose (mg/day)

50 (0–400)

50 (0–400)

50 (0–150)

0.24

 Branched-chain amino acid (%)

150/170 (88%)

76/90 (84%)

35/37 (95%)

0.12

 CART or drainage (%)

84/170 (49%)

47/90 (52%)

15/37 (41%)

0.37

 Denver shunt

6 (4%)

1 (1%)

3 (8%)

0.04

Laboratory data

 Albumin (g/dL)

2.4 (1.5–4.2)

2.4 (1.6–3.6)

2.6 (1.7–4.2)

0.03

 Total bilirubin (mg/dL)

1.9 (0.3–52.4)

2.2 (0.3–52.4)

2.0 (0.4–21.7)

< 0.01

 Aspartate aminotransferase (U/L)

48 (10–551)

52 (12–551)

42 (13–171)

0.06

 Alanine aminotransferase (U/L)

28 (3–381)

29 (3–381)

29 (7–144)

0.53

 γ-Glutamyl transpeptidase (U/L)

49 (9–269)

52 (9–269)

48 (9–229)

0.28

 Platelet count (×104/μL)

8.8 (1.5–62.7)

8.8 (2.1–62.7)

7.6 (1.5–23.9)

0.10

 Prothrombin time (PT%)

55.6 (16.3–90.3)

52.5 (16.3–89.0)

54.5 (19.5–90.3)

0.22

 PT/INR

1.31 (0.98–3.17)

1.33 (1.04–3.17)

1.32 (0.98–2.84)

0.36

 Ammonia (μg/dL)

66 (16–269)

60 (24–212)

85 (25–269)

0.11

 α-fetoprotein (ng/mL)

4 (1–142,010)

4 (1–142,010)

4 (1–210)

0.13

 Des-gamma-carboxy (mAU/mL)

68 (3–357,790)

73 (5–357,790)

27 (3–4994)

0.26

 Blood urea nitrogen (mg/dL)

20.9 (5.5–125.3)

22.5 (5.8–64.3)

23.2 (6.0–63.3)

0.86

 Creatinine (mg/dL)

0.99 (0.20–3.30)

1.00 (0.20–2.87)

1.04 (0.44–3.30)

0.28

 eGFR (mL/min/1.73 m2)

53.9 (14.9–250.6)

53.1 (14.9–250.6)

49.5 (16.8–107.2)

0.06

 Serum sodium (mEq/L)

136 (118–145)

135 (118–143)

137 (122–145)

0.01

 Modified Child-Pugh (CP) score

11 (6–14)

11 (8–14)

11 (8–13)

0.05

 MELD score

12 (1–37)

14 (1–37)

12 (2–29)

0.53

  1. n number of patients, BW body weight, HCV hepatitis C virus, HBV hepatitis B virus, ALD alcoholic liver disease, NAFLD non-alcoholic fatty liver disease, PBC primary biliary cholangitis, CART cell-free and concentrated ascites reinfusion therapy, eGFR estimated glomerular filtration rate, INR international normalized ratio, MELD model for end-stage liver disease. Data are represented as the median (range)